Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

2.8K
2.8K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

9.5K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.5K
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

726
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
726
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

1.2K
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
1.2K
Amyloid Fibrils03:03

Amyloid Fibrils

13.2K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
13.2K
Amyloid Fibrils03:03

Amyloid Fibrils

7.0K
7.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Authors' Response to the Letter Titled: Enhancing Treatment Resilience in Palliative Oesophago-Gastric Cancer: Nutritional, Access, and Scoring Considerations.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Proceedings from the Third International Post-Tuberculosis Symposium: expanding the circle.

IJTLD open·2025
Same author

Factors Affecting Treatment Resilience in Patients With Oesophago-gastric Cancers Undergoing Palliative Chemotherapy: A Rapid Review.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

Mean-field approximation for networks with synchrony-driven adaptive coupling.

Chaos (Woodbury, N.Y.)·2025
Same author

Group B Streptococcal Management in Penicillin-allergic Pregnant Women.

Irish medical journal·2024
Same author

Perspectives from the 2<sup>nd</sup> International Post-Tuberculosis Symposium: mobilising advocacy and research for improved outcomes.

IJTLD open·2024

Related Experiment Video

Updated: Apr 17, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

6.4K

Binding Interactions of Agents That Alter α-Synuclein Aggregation.

K Sivanesam1, A Byrne1, M Bisaglia2

  • 1Department of Chemistry, University of Washington, Seattle, WA 98195.

RSC Advances
|February 24, 2015
PubMed
Summary

New peptide inhibitors targeting alpha-synuclein amyloid formation show enhanced potency. The most effective inhibitor, cyclo-WW2, prevents beta-structure formation and binds key aggregation sites, offering a promising therapeutic lead.

Keywords:
NMR titration shiftsParkinson’s diseaseamyloidogenesisβ-hairpins

More Related Videos

A Method to Study &#945;-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

8.1K

Related Experiment Videos

Last Updated: Apr 17, 2026

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils
15:04

Interactions with and Membrane Permeabilization of Brain Mitochondria by Amyloid Fibrils

Published on: September 28, 2019

6.4K
A Method to Study &#945;-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.8K
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation
09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

8.1K

Area of Science:

  • Biochemistry
  • Neuroscience
  • Drug Discovery

Background:

  • Alpha-synuclein aggregation into amyloid fibrils is central to Parkinson's disease pathogenesis.
  • Developing small peptides to inhibit alpha-synuclein amyloid formation is a key therapeutic strategy.
  • Previous inhibitors sometimes promote non-amyloid aggregate formation, necessitating improved designs.

Purpose of the Study:

  • To design and identify more potent peptide inhibitors of alpha-synuclein amyloid formation.
  • To elucidate the mechanism of inhibition and binding sites of effective peptide inhibitors.
  • To investigate the early stages of alpha-synuclein aggregation using biophysical techniques.

Main Methods:

  • Synthesis and characterization of novel peptide inhibitors, including backbone cyclized variants.
  • Inhibition assays to assess the effect of peptides on alpha-synuclein beta-structure formation.
  • Nuclear Magnetic Resonance (NMR) spectroscopy (15N HSQC) to study alpha-synuclein-peptide interactions and aggregation dynamics.

Main Results:

  • Several new peptides, particularly those with multiple tyrosine residues and Trp-bearing structures, demonstrated potent inhibition.
  • The backbone cyclized peptide cyclo-WW2, featuring a Trp/Trp cluster, completely inhibited beta-structure formation at a 2:1 ratio.
  • NMR studies revealed that effective inhibitors bind to the C-terminal segment (Q109-E137) of alpha-synuclein, with cyclo-WW2 also binding to the G41-T54 region.
  • NMR data provided mechanistic insights into early aggregation, identifying H50 as a critical residue and a binding site for cyclo-WW2.

Conclusions:

  • Peptides incorporating antiparallel beta-strands, especially with Trp residues and specific cyclization strategies, are highly effective inhibitors of alpha-synuclein amyloidogenesis.
  • Cyclo-WW2 represents a lead compound for developing small peptide inhibitors that specifically block amyloid formation without promoting alternative aggregation pathways.
  • Understanding the binding sites and early aggregation mechanisms via NMR is crucial for designing targeted therapeutic interventions for synucleinopathies.